Showing results (381-390 of 7,002) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLCA A Bokhari, W-Y Lai, A T Le, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2022
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)Yuji Minegishi, Tomoe Akagami, Makoto Arai, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2021
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC eraFrancesco Passiglia, Gianmarco Leone, Emanuela Olmetto, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2021
Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized studyJarosław Kużdżał, Łukasz Trybalski, Łukasz Hauer, et al.
Lung Cancer (Amsterdam, Netherlands)|June 25, 2020
Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancerWenxian Wang, Guoping Cheng, Gu Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 23, 2015
Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumorsAadel A Chaudhuri, Chad Tang, Michael S Binkley, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Mixed mucoepidermoid carcinoma and adenocarcinoma of the lung: Two cases with unusual histologic featuresMin-Shu Hsieh, Yi-Hsuan Lee, Jin-Shing Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 8, 2015
Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survivalYan Jin, Ping-Li Sun, Soo Young Park, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2020
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancerMartin Reck, Alexander Luft, Igor Bondarenko, et al.
Lung Cancer (Amsterdam, Netherlands)|June 8, 2020
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patientMunehiro Ito, Shintaro Kanda, Tatsuya Yoshida, et al.
Pageof 701